Gilead Sciences, Inc. $GILD Shares Bought by Lido Advisors LLC

Lido Advisors LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 159,191 shares of the biopharmaceutical company’s stock after purchasing an additional 5,366 shares during the period. Lido Advisors LLC’s holdings in Gilead Sciences were worth $23,728,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Bank of Nova Scotia acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at $100,056,000. OMERS ADMINISTRATION Corp purchased a new stake in Gilead Sciences in the 2nd quarter valued at $55,754,000. Groupe la Francaise raised its position in Gilead Sciences by 30.9% in the 2nd quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock valued at $6,270,000 after purchasing an additional 11,712 shares during the last quarter. Baird Financial Group Inc. raised its position in Gilead Sciences by 3.6% in the 2nd quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock valued at $36,929,000 after purchasing an additional 10,206 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in Gilead Sciences during the 2nd quarter worth $6,251,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 0.7%

NASDAQ:GILD opened at $169.73 on Thursday. The firm has a market cap of $210.52 billion, a P/E ratio of -53.71 and a beta of 0.35. The company has a current ratio of 1.38, a quick ratio of 1.22 and a debt-to-equity ratio of 1.84. The stock’s 50 day simple moving average is $154.40 and its 200-day simple moving average is $141.51. Gilead Sciences, Inc. has a 12-month low of $116.88 and a 12-month high of $176.58.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The business had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. During the same quarter in the prior year, the business earned $2.47 earnings per share. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. Equities analysts anticipate that Gilead Sciences, Inc. will post -0.98 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s payout ratio is -103.80%.

Gilead Sciences News Summary

These are some of the GILD news items that stood out recently:

• Positive Sentiment: Gilead reported PURPOSE 5 results showing twice-yearly injectable lenacapavir outperformed daily oral HIV prevention on persistence, with no HIV infections in the injectable group. The findings could strengthen the long-term opportunity for its HIV prevention franchise. Gilead Sciences Posts PURPOSE 5 Win As HIV Shot Beats Daily Pills
• Neutral Sentiment: Gilead partner Xilio expects to provide Gilead with an option data package for efarindodekin alfa in the first half of 2027. This is a potential pipeline catalyst, but remains several months away and is dependent on future data. Xilio Therapeutics Pipeline Update
• Negative Sentiment: Potential U.S. drug-price negotiations pose a near-term risk to Gilead’s revenue, adding a policy overhang even as its clinical and commercial prospects improve. Drug Pricing Risks As Washington Turns Up Heat

Wall Street Analyst Weigh In

Several research analysts have issued reports on GILD shares. Bank of America raised their price objective on shares of Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a research report on Tuesday, October 20th. Weiss Ratings upgraded shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Scotiabank upped their target price on shares of Gilead Sciences from $177.00 to $200.00 and gave the company a “sector outperform” rating in a report on Friday, October 30th. BMO Capital Markets reiterated an “outperform” rating and set a $184.00 target price on shares of Gilead Sciences in a research note on Friday, October 30th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $175.00 target price on shares of Gilead Sciences in a research note on Monday, November 2nd. Twenty-three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.15.

Insider Buying and Selling at Gilead Sciences

In related news, CEO Daniel O’Day sold 102,619 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $175.16, for a total value of $17,974,744.04. Following the completion of the sale, the chief executive officer owned 551,683 shares in the company, valued at $96,632,794.28. This trade represents a 15.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the sale, the insider owned 118,234 shares of the company’s stock, valued at approximately $16,273,727.76. The trade was a 19.15% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 242,709 shares of company stock valued at $39,503,427. Insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.